CAR-T– tag –
-
CAR-T Expands to Solid Tumors & Autoimmune Diseases; BAF CAR-T Shows Promising Early Results for Lupus, Compared with Off-the-Shelf CAR-NK Cells
University Hospitals USA Overview CAR-T cell therapy is expanding its success from hematologic malignancies to solid tumors and autoimmune diseases. Notably, early clinical trial results for BAF CAR-T in lupus are highly promising, sugge... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a... -
CRISPR Medicine News Roundup: Sickle Cell CRISPR Drug Shows Potent Results in Young Children, Caribou’s Off-the-Shelf CAR-T Delivers Positive Phase 1 Data
CRISPR Medicine News USA Overview A CRISPR Medicine News summary article reports that the first approved CRISPR gene therapy for sickle cell disease demonstrated equally potent results in children as young as 5 years old. Additionally, C... -
Tacit Knowledge Loss in Cell & Gene Therapy Tech Transfer Poses Critical Threat to Manufacturing Yield and Quality
Drug Discovery and Development USA Overview The transfer of cell and gene therapy manufacturing processes is severely hampered by the loss of tacit knowledge, impacting product yield and quality. Manual steps in CAR-T cell production, su... -
Genomic Engineering Strategies and Alternative Cell Types in Allogeneic T-Cell Immunotherapy Platforms Enable Scalable Cancer Treatment
Academic Publication Global Overview Allogeneic T-cell therapy is emerging as a highly promising strategy in cancer immunotherapy due to its scalability and 'off-the-shelf' availability, overcoming logistical and manufacturing constraint... -
Allogeneic CAR-T Cell Therapies Promise to Overcome Autologous Challenges and Expand Therapeutic Potential in Solid Tumors
PubMed (Review Article) Global Overview This review article details how allogeneic CAR-T cell therapies demonstrate clinical benefits in B-cell malignancies and offer the potential to overcome key limitations of autologous CAR-T, such as... -
CRISPR Gene Editing Advances in 2026: Accumulation of Clinical Data and Evolving Regulatory Framework for Rare Diseases, Cancer, and Autoimmune Disorders
Industry report / Analysis USA Overview The CRISPR gene editing landscape in 2026 shows significant progress across rare diseases, hematologic and solid cancers, and autoimmune disorders. Clinical programs are generating crucial data, wh... -
CRISPR Therapeutics Stock Volatility Driven by CASGEVY Commercialization and CTX112 Clinical Progress
Investing.com USA Overview CRISPR Therapeutics has experienced significant stock volatility due to market reactions to the commercialization of its approved CRISPR gene therapy, CASGEVY, and clinical developments for its off-the-shelf CA... -
Nkarta Develops Off-the-Shelf NK Cell Therapies NKX019 and NKX101 for Solid and Hematologic Malignancies, Balancing Scalability with Clinical Efficacy
Umbrex USA Overview Nkarta, a clinical-stage biotechnology company, specializes in off-the-shelf NK cell therapies derived from healthy donors, developing NKX019 for B-cell malignancies and NKX101 for Acute Myeloid Leukemia (AML) as its ... -
Advancing Cell Therapy Production: CCRM, OmniaBio, and Avectas Pioneer Automated Hub-and-Spoke Model for CAR-T, iPSC, and Lentiviral Vectors
PR Newswire (CCRM) Canada, アイルランド Overview CCRM and its CDMO subsidiary, OmniaBio, have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This strategic alliance ...
